Aviptadil
Also called VIP, RLF-100
Intravenous (into a vein)Human study reference
Research reference
Human study
TESICO hospital trial
12-hour IV infusions on each of 3 days, with weight-based escalation
3-day exposure; primary clinical outcome through day 90
TESICO, Lancet Respiratory Medicine (2023) ↗When results may show
- When change was measured
- The trial stopped for futility and did not show a significant improvement in its day-90 clinical outcome.
- When to assess
- 3-day exposure; primary clinical outcome through day 90
- Conditions and limitations
- Hospitalized adults with COVID-19 hypoxaemic respiratory failure. A hospital infusion protocol is not a home injection or inhaled-product schedule. Negative findings must not be presented as expected benefit.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 0.90× single dose
- Time to steady state
- 0hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- TESICO, Lancet Respiratory Medicine (2023)A hospital infusion protocol is not a home injection or inhaled-product schedule. Negative findings must not be presented as expected benefit.